Featured Tickers:
Sifting through countless of stocks in the Health Care Providers & Services industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Progyny, Inc. or GeneDx Holdings Corp. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.
Read on to learn how Progyny, Inc. and GeneDx Holdings Corp. compare based on key financial metrics to determine which better meets your investment needs.
About Progyny, Inc. and GeneDx Holdings Corp.
Progyny, Inc., a benefits management company, provides fertility, family building, and women’s health benefits solutions in the United States. The company offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. It also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services. In addition, the company offers assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
GeneDx Holdings Corp., a genomics company, provides genetic testing services. It primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. The company also develops an AI-based platform for NGS analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. The company is headquartered in Stamford, Connecticut.
Latest Health Care Providers & Services and Progyny, Inc., GeneDx Holdings Corp. Stock News
As of July 8, 2025, Progyny, Inc. had a $2.1 billion market capitalization, compared to the Health Care Providers & Services median of $995.1 million. Progyny, Inc.’s stock is up 36.9% in 2025, up 7% in the previous five trading days and down 14.12% in the past year.
Currently, Progyny, Inc.’s price-earnings ratio is 42.8. Progyny, Inc.’s trailing 12-month revenue is $1.2 billion with a 4.3% net profit margin. Year-over-year quarterly sales growth most recently was 16.5%. Analysts expect adjusted earnings to reach $1.618 per share for the current fiscal year. Progyny, Inc. does not currently pay a dividend.
As of July 8, 2025, GeneDx Holdings Corp. had a $2.4 billion market cap, putting it in the 60th percentile of all stocks. GeneDx Holdings Corp.’s stock is up 19.5% in 2025, up 1.7% in the previous five trading days and up 204.36% in the past year.
Currently, GeneDx Holdings Corp. does not have a price-earnings ratio. GeneDx Holdings Corp.’s trailing 12-month revenue is $330.1 million with a -11.7% net profit margin. Year-over-year quarterly sales growth most recently was 39.6%. Analysts expect adjusted earnings to reach $1.073 per share for the current fiscal year. GeneDx Holdings Corp. does not currently pay a dividend.
How We Compare Progyny, Inc. and GeneDx Holdings Corp. Stock Grades
Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.
AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Progyny, Inc. and GeneDx Holdings Corp.’s stock grades to see how they measure up against one another.
Learn more about A+ Investor here!
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions